Robert K. Suto, Ph.D., Chairman
Robert Suto is the President and CSO of Xtal BioStructures. As a biochemist with a thorough knowledge of structure-guided drug discovery, he has been involved in the discovery and development projects of over sixty companies. Prior to co-founding Xtal BioStructures, Mr. Suto served as a lead scientist at Pintex Pharmaceuticals, Inc., a startup company focused on the development of structure-based cancer therapeutics and diagnostics.
Stefan Gruenwald, M.D., PhD. is the Co-Founder of Diagnomics, one of DNA-SEQ’s key strategic partners. His long career in life sciences includes being the VP of R&D of PharMingen (now a part of BD Bioscience) where his R&D lab cloned over 1,300 genes and expressed more than 200 proteins in various protein expression systems. Mr. Gruenwald then went on to co-found Orbigen, a San Diego-based proteomics company. Orbigen developed over 3,000 products in a dozen different areas ranging from proteomics to immunology. In 2004, Mr. Gruenwald was crucial in negotiating the merger between Orbigen and Jingmei, the second largest Biotech reagent company in China.
Walter Gilbert, PhD.
Walter Gilbert, PhD., is renowned for his work in Molecular Biology on genetics and DNA. He was awarded, along with Fred Sanger in England, the Nobel Prize in Chemistry in 1980 for finding ways to decipher the order of chemical groups along the DNA molecule, making it possible to read the genes for the first time. Those discoveries drove the development of Biology as a gene-based science across the last three decades and led to the working out of the Human Genome program and the current understanding of all organisms. Mr. Gilbert was educated at Harvard University and Cambridge University, Cambridge, England. He was a professor at Harvard for many years, first in Physics and later in Biology.
Stuart Siegel, M.D.
Stuart Siegel, M.D., is an internationally recognized oncologist known for his expertise in children’s hematological oncology. His dedication to young patients is recognized internationally through numerous awards and his current community work includes work on behalf of the following institutions: National Leukemia Broadcast Council, Leukemia Society of America-Los Angeles Chapter, Camp Ronald McDonald for Good Times, and others. He is the Professor of Pediatrics, and Head of the Division of Hematology-Oncology at Children’s Hospital of Los Angeles and Keck School of Medicine of USC. He has authored over 250 peer-reviewed articles and book chapters, most dealing with children’s hematological cancers.
Thomas M. Wheeler, M.D.
Thomas M. Wheeler, M.D., is an internationally recognized pathologist known for his expertise in prostate cancer. He is the W. L. Moody, Jr., Professor and Chair, Department of Pathology & Immunology at Baylor College of Medicine. He is actively involved with the CancerGenetics Laboratory (CGL) at Baylor, a leading laboratory with cutting edge technology in molecular cancer diagnostics. He is the past chair of the Council on Scientific Affairs for the College of American Pathologists. He has authored approximately 300 peer-reviewed articles and book chapters, most dealing with prostate cancer.
Tony Hunter, M.D.
Tony Hunter is one of the foremost recognized leaders in the field of cell growth control, growth factor receptors and their signal transduction pathways. He is a Professor in the Molecular and Cell Biology Laboratory and Director of the Salk Institute Cancer Center, studies how cell growth and division are regulated, and how mutations in genes that control growth lead to cancer. His group has made significant contributions in the area of signal transduction, elucidating how signals that stimulate or inhibit proliferation are transmitted within a cell.